The Rise of Fake Retatrutide & a Chemical Analysis of what it is...
You've probably heard of the incoming Retatrutide - the latest weight loss medication currently in clinical trials to ascertain its safety for human use. But as we have previously highlighted, there has become a dark side to these weight loss medications.
Retatrutide is not authorised for use anywhere in the world yet so many people are buying it and using it... and not via official channels. They are obtaining it via unregistered websites, social media users and even personal trainers at their local gym.
For prescription-only weight-management medicines, a qualified prescriber and a legitimate, regulated supply route is vital to your safety. [2,3]
A recent Futurism article described laboratory testing of a product claiming to be Retatrutide that was bought from an American convenience shop (see the results below). The concern goes beyond whether an injection will help someone lose weight safely: it now includes whether the medication contains a genuine and safe product. [1]
At AJ Hill Aesthetics, our message is simple: you deserve clear information, appropriate clinical care and medicines you can trust.
“What is retatrutide, and why is everyone talking about it?”
Retatrutide is an investigational medicine being developed by Eli Lilly. It acts on three hormone receptors: GLP-1, GIP and glucagon. These pathways are involved in appetite, blood glucose regulation and energy metabolism. You may see it described online as a “triple agonist” or simply “Reta”. [3]
In a published phase 2 trial involving 338 adults with obesity or overweight and a weight-related condition, researchers observed substantial weight loss over 48 weeks. The highest-dose group had an average reduction of approximately 24% of starting body weight. [4]
However, this was a controlled study, involving selected participants, a defined study medicine and clinical monitoring. The result does not tell us what will happen to someone injecting an unknown product bought through a private message.
It also does not mean that a higher dose is a better or safer choice. Research results are findings for scientists and regulators to assess, not instructions for self-treatment.
“Is retatrutide approved in the UK?”
No. As of October 2026, retatrutide has not been authorised for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has explicitly warned against products sold under its name. [2]
Lilly also states that retatrutide remains investigational and is available only to participants in its clinical trials. A consumer offer of “genuine Lilly retatrutide” should therefore raise immediate concern. [3]
Medicines approval is an important safeguard. Regulators assess evidence about a medicine’s quality, safety and effectiveness, including whether its benefits outweigh its risks for the intended patients.
At this time, Retatrutide should not be presented as a private prescription option or an early-access treatment. Obtaining Retatrutide whilst unapproved for human use is different to a clinician prescribing an authorised medicine “off-label”. That term usually describes using a licensed medicine outside its approved indication or other licence conditions for a use that has been researched & shown to be of benefit.
“What did the investigation actually find?”
Futurism reported on a CBS News investigation in which a product labelled as retatrutide was purchased from a Brooklyn convenience shop and sent for analysis.
To test what’s actually in a bodega vial labeled “retatrutide,” the news outlet sent samples to Jason Galpin, a researcher of bioorganic chemistry at the University of Iowa. His analysis? “It does not look anything like a peptide,” he told CBS.
In place of any sort of peptide-like-substance — which should be made up of short chains of amino acids — Galpin discovered the vial was chock full of phenylacetic acid, a filler-compound typically used in perfume and illicit amphetamine manufacturing.
Worse yet, the vial also contained at least 13 various bacterial colonies, which director of development at the University of Iowa’s Center for Biocatalysis and Bioprocessing Carl Ross told CBS could easily cause a dangerous infection.
“As kids, we’re all taught to wash out cuts if we get cut,” Ross explained. With gray market peptides, however, users are “injecting bacteria under the skin where it could multiply. It’s pretty terrifying.”
Last month, Wired conducted a similar analysis, buying “peptides” from a bodega in Brooklyn and sending them to a lab for analysis. As with CBS, it turned out that they weren’t peptides at all; instead, they found chemical slurry that technicians couldn’t even identify.
Those findings relate to the sample investigated. They do not establish the contents of every product sold as retatrutide, and this was a news investigation rather than a peer-reviewed survey of the market.
Nevertheless, it illustrates an important safety problem: a name on a vial is not proof of its contents. Neither attractive packaging nor a confident sales pitch can establish that something is suitable for injection.
The UK has its own reason for concern. On 15 October 2026, the MHRA announced a seizure of more than 12,000 fake retatrutide and tirzepatide pens in Birmingham. The fake Retatrutide is well & truly in the UK and is being used by thousands of people. [2]
“What are the risks of taking it before approval?”
There are two connected concerns: the uncertainties around the investigational medicine itself, and the additional hazards of whatever an unofficial seller supplies.
Side effects still need careful assessment
In the phase 2 obesity trial, gastrointestinal side effects were the most common adverse events. They were dose-related and generally mild to moderate. Researchers also observed dose-dependent increases in heart rate. [4]
That does not mean every person will have those effects, or that they are the only possible risks. Studies must assess a much broader picture, including less common harms, longer-term outcomes and which patients may be particularly vulnerable.
An online testimonial cannot answer those questions. Someone saying they “felt fine” after several injections does not demonstrate that the treatment is safe for you.
The contents and strength may be unreliable
Lilly warns that illicit retatrutide products may contain incorrect ingredients, impurities or harmful contaminants, and too much or too little active ingredient. [3]
Even if a substance produces appetite suppression, that does not authenticate it. A physical effect is not a quality test.
Injectable products need more than a convincing label
For something injected beneath the skin, sterility matters. Contamination can introduce infection, and infection can sometimes become serious. Sepsis is a life-threatening reaction to infection that requires urgent treatment. [8]
A vial can look clear and still be unsafe. You cannot assess sterility, chemical identity or suitability for injection by looking at it.
There may be no meaningful clinical oversight
Without proper assessment, important questions can be missed: your medical history, other medicines, previous adverse reactions, pregnancy plans, nutritional needs and whether a weight-management medicine is appropriate at all.
Follow-up and aftercare matters too. A person selling you a vial may have no safe process for assessing symptoms, arranging investigations or responding when something goes wrong. Where is the safety net if something goes wrong?
“Does ‘research use only’ or a purity certificate make it safer?”
No. “Research use only” is not reassurance that a product is suitable for people. It does not authorise self-injection or remove the need for medicines regulation.
Likewise, a certificate stating “99% purity” cannot, by itself, answer every important safety question. You would still need to know whether it is authentic, which sample was tested, whether it corresponds to the supplied batch, and what the testing actually measured.
Chemical purity, accurate concentration, sterility and stability are different questions. A result addressing one does not automatically settle the others.
Be particularly cautious if a seller sends mixing instructions, encourages you to calculate your own doses or says a disclaimer means the usual safeguards do not apply. Do not try to make an unverified product safe by preparing it more carefully at home.
“Why does an official UK supply chain matter?”
When you receive a medicine, you are relying on much more than its active ingredient. Manufacturing standards, sourcing, transport, storage and dispensing all contribute to its quality.
A legitimate UK supply route provides accountability: there should be identifiable organisations responsible for prescribing and supplying your medicine, and a way to raise concerns or act on a recall.
For a prescription-only weight-management medicine, the safe route is an appropriate clinical assessment, a valid prescription and supply through a registered pharmacy or other lawful clinical supply arrangement. The MHRA advises people seeking GLP-1 treatment to obtain medicines from a registered pharmacy against a valid prescription. [2,5]
Ask who will dispense your medicine and whether it is sourced through authorised manufacturers and licensed wholesalers. If a clinic arranges delivery, you should still be able to identify the dispensing pharmacy.
“UK stock”, “pharmaceutical grade” and “straight from the manufacturer” are sales claims, not independent verification. A UK address or next-day delivery cannot establish a lawful supply chain.
Who are you buying from?
With the rise of Retatrutide, weight loss medications and peptides becoming more available from personal trainers, salons, gym contacts or people selling through social media, it is important to know if your product is coming from a genuine source.
If it is a medication, this should come via an official supplier, such as a registered clinic (in person or online), a pharmacy or via your doctor.
You may know and trust the person offering them weight-loss injections. They may believe the product is genuine. But you should never buy the mediation off someone who is not medically qualified. Without obtaining the product directly for yourself from a registered provider, neither personal trust nor someone else’s good experience can verify its manufacture, contents or storage history.
It may have worked well for them and got them the results they wanted, but everyone is different, and you may have a very different reaction.
Whilst a regulated clinician may work from premises that also offer beauty treatments, the important questions remain the same: who is assessing you, are they appropriately registered and qualified, and where is the medicine being dispensed?
Similarly, a legitimate healthcare provider may have a social media page. That is different from buying injections through influencers online. Assess the actual clinical service and supply route, rather than the number of followers or comments (which could be AI bots posting falsely positive reviews).
“What if I have already bought or used it?”
Please do not feel embarrassed about seeking help. Honest information helps healthcare professionals look after you.
If you have bought a product sold as retatrutide outside a legitimate clinical trial, do not inject it. If you have already used it, do not take another dose and contact a pharmacist, GP or NHS 111 for advice. This advice concerns the unverified product.
Keep the packaging, seller details, batch information and a record of what you took and when. Do not use or share the remaining product.
Seek urgent medical advice for persistent vomiting, inability to keep fluids down or a painful, hot, swollen injection site. Sudden severe abdominal pain needs urgent assessment; if it spreads to your back or occurs with breathing difficulty or a fast heartbeat, call 999 or go to A&E. [7]
Call 999 for collapse, severe breathing difficulty, or signs of a serious reaction such as throat swelling. Confusion, very fast breathing or blue, pale or blotchy skin can also indicate a medical emergency. Do not wait for a seller to respond. [8]
Suspected side effects or concerns about fake medicines can be reported through the MHRA Yellow Card scheme. Reporting does not replace medical care. [9]
This article provides general patient information and does not replace an individual clinical assessment. Regulatory information can change.
References and further reading
Futurism (24 October 2026). Someone Ran a Chemical Analysis of Bodega Retatrutide and Dear Lord. Reporting that prompted this article.
MHRA (15 October 2026). Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police.
Eli Lilly. What to know about retatrutide. Manufacturer information on investigational status and illicit products.
Jastreboff AM et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526. doi:10.1056/NEJMoa2301972. Lilly-funded trial.
MHRA (24 July 2026). No summer shortcut for safe weight loss.
UK Parliament (1 September 2025). Written answer: safe access to weight-loss medicines. Pharmacy checks: GPhC registers; PSNI registers.
NHS. Acute pancreatitis.
NHS. Sepsis.
MHRA. Yellow Card reporting scheme.
Sources accessed 28 October 2026.
